Clinical research center

Parthenon Therapeutics Appoints Joseph Paul Eder, MD, as Chief Medical Officer

Retrieved on: 
Thursday, December 15, 2022

Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.

Key Points: 
  • Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.
  • We are excited to welcome Dr. Joseph Paul Eder to Parthenon as Chief Medical Officer.
  • His experience also extends to the pharmaceutical industry where he was Senior Medical Science Director & Global Clinical Medical Director, Hematology at AstraZeneca, PLC.
  • Dr. Eder is Chief Medical Officer at Parthenon, bringing over 30 years of clinical experience at leading cancer research institutions as well as the pharmaceutical industry.

Brooks Rehabilitation Ranked Number One in Florida on Newsweek's "America's Best Physical Rehabilitation Centers 2022" List

Retrieved on: 
Wednesday, October 12, 2022

They are honored that their high-quality care was recognized on Newsweek's "America's Best Physical Rehabilitation Centers 2022" list.

Key Points: 
  • They are honored that their high-quality care was recognized on Newsweek's "America's Best Physical Rehabilitation Centers 2022" list.
  • Brooks Rehabilitation Hospital was ranked the number one facility in Florida.
  • Doug Baer, Brooks Rehabilitation President & CEO, said, "Brooks is known for our exceptional patient outcomes, cutting-edge technology and world-class clinical research.
  • For more than 50 years, the nonprofit Brooks Rehabilitation has been a comprehensive, complete system of care for physical rehabilitation.

Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future

Retrieved on: 
Monday, September 26, 2022

KGK will host a grand opening ceremony on September 29, 2022 to officially open the new, state-of-the-art clinical research facility and celebrate being a leading contract research organization for over 25 years.

Key Points: 
  • KGK will host a grand opening ceremony on September 29, 2022 to officially open the new, state-of-the-art clinical research facility and celebrate being a leading contract research organization for over 25 years.
  • The Companys clinical research center empowers KGK to provide high-quality clinical research trials and expert regulatory support for clients in the nutraceutical, cannabis, hemp and psychedelic industries.
  • As a premium full-service contract research organization, KGK is dedicated to providing clinical trial research that meets the highest quality standards.
  • Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products.

Brooks Rehabilitation participates in national stroke recovery trial using breakthrough technology

Retrieved on: 
Thursday, September 22, 2022

JACKSONVILLE, Fla., Sept. 22, 2022 /PRNewswire/ -- Brooks Rehabilitation's first participant in the national stroke recovery trial, EMAGINE, has just completed study participation.

Key Points: 
  • JACKSONVILLE, Fla., Sept. 22, 2022 /PRNewswire/ -- Brooks Rehabilitation's first participant in the national stroke recovery trial, EMAGINE, has just completed study participation.
  • The EMAGINE stroke recovery trial will enroll 150 randomized subjects nationwide 4-21 days following a stroke.
  • For more than 50 years, Brooks Rehabilitation, headquartered in Jacksonville, Fla., has been a comprehensive source for physical rehabilitation services.
  • BrainQ, the EMAGINE Stroke Recovery Trial sponsor, is a US and Israel-based company pioneering a novel therapy for reducing disability and maximizing the recovery potential for stroke and other neurodisorder victims.

Brooks Rehabilitation Continues Growth in Central Florida, Plans to Add New and Expanded Outpatient Clinics at Least through 2024

Retrieved on: 
Monday, August 8, 2022

ORLANDO, Fla. and JACKSONVILLE, Fla., Aug. 8, 2022 /PRNewswire/ -- As part of its continued growth and community commitment to Orlando/Central Florida, Brooks Rehabilitation anticipates opening and expanding its outpatient clinics in the market through at least 2024. Brooks had five locations in the Orlando area in January 2022, and it anticipates growing to 11 clinics locally by January 2023. Brooks is also exploring all sub-markets of Orlando for future growth.

Key Points: 
  • Brooks' newest location, in Clermont, is scheduled to open in early September and will provide tri-disciplinary outpatient services of PT, OT and SLP.
  • "There is a tremendous need in the Central Florida market for immediate access to quality outpatient rehabilitation services," said Tom Langer, PT, CSCS, Brooks Rehabilitation outpatient regional director, Orlando.
  • For more than 50 years, Brooks Rehabilitation, headquartered in Jacksonville, Fla., has been a comprehensive source for physical rehabilitation services.
  • For more than 50 years, Brooks Rehabilitation, headquartered in Jacksonville, Fla., has been a comprehensive source for physical rehabilitation services.

Brooks Rehabilitation Opens Additional Inpatient Rehabilitation Hospital

Retrieved on: 
Wednesday, April 20, 2022

JACKSONVILLE, Fla., April 20, 2022 /PRNewswire/ -- Brooks Rehabilitation is now welcoming patients to its new 60-bed, state-of-the-art inpatient rehabilitation hospital. The additional 76,056 sq. ft. hospital is located on its existing 115-acre campus in the Bartram Park area of Jacksonville, Fla.

Key Points: 
  • JACKSONVILLE, Fla., April 20, 2022 /PRNewswire/ -- Brooks Rehabilitation is now welcoming patients to its new 60-bed, state-of-the-art inpatient rehabilitation hospital.
  • ft. hospital is located on its existing 115-acre campus in the Bartram Park area of Jacksonville, Fla.
    Brooks Rehabilitation is now welcoming patients to its new 60-bed, state-of-the-art inpatient rehabilitation hospital.
  • Brooks Rehabilitation Hospital Bartram Campus joins Brooks' two existing rehabilitation hospitals to meet the demands of a growing population .The original 160-bed rehabilitation hospital on University Blvd.
  • Brooks also manages a 40-bed inpatient rehabilitation hospital in partnership with Halifax Health in Daytona Beach, Fla.
    Frontline staff members were actively involved in the design of the new Bartram hospital.

A Free Health Education Event On Clinical Research Will Be Held March 9th In Birmingham

Retrieved on: 
Monday, February 7, 2022

This free event is open to the public and will be held March 9th, from 5-8 PM at The Harbert Center in downtown Birmingham, AL.

Key Points: 
  • This free event is open to the public and will be held March 9th, from 5-8 PM at The Harbert Center in downtown Birmingham, AL.
  • The event is tailored for the Birmingham community, featuring local clinical trial participants, healthcare professionals, and exhibiting organizations.
  • To register for the Birmingham event visit: https://www.ciscrp.org/event/aware-for-all-birmingham/
    The Journey to Better Health | AWARE for All - Birmingham event is supported by local research teams, advocacy groups, and a consortium of biopharmaceutical and service provider companies.
  • The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process.

Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Retrieved on: 
Monday, December 20, 2021

FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today the enrollment and randomization of the first patient, with several more in screening for an initial study to evaluate STAT-205 as a potential treatment to mitigate SARS-CoV-2 progression, the virus that causes COVID-19. STAT-205 is an immune-modulator designed to decrease elevated inflammatory responses associated with cytokine production and modulate the Th1/Th2 helper cells to control immune dysfunction.

Key Points: 
  • Now that vaccines are widely available, developing safe and effective treatments for people who contract COVID-19 is our next challenge.
  • I am excited that our site has randomized the first patient in the clinical trial of STAT-205.
  • The study is designed to assess the pharmacokinetics (PK), early predictive biomarkers, and safety of STAT-205.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

DGAP-News: XPhyto Therapeutics Corp.: XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips

Retrieved on: 
Monday, December 20, 2021

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips.

Key Points: 
  • VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips.
  • Prof. Dr. Beckert said, "the clinical trial of our CBD product is aiming to demonstrate the efficient and precise dosing of the treatment.
  • If successful, this could make a significant difference to Epilepsy patients and we are excited to commence the trial next year."
  • XPhyto is developing a hybrid-generic CBD prescription drug formulation that employs the Company's proprietary oral dissolvable ("ODF") platform to deliver precise and efficient CBD dosages for the treatment of certain forms of childhood Epilepsy.

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

Retrieved on: 
Monday, November 1, 2021

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, this week presented the first-ever data on the health-related quality of life (HRQOL) and experience of patients with Bardet-Biedl syndrome (BBS) who were treated in its Phase 3 trial of setmelanotide at The Obesity Society’s ObesityWeek®, a virtual conference that runs from Nov. 1 to 5.   

Key Points: 
  • Elizabeth Forsythe, Ph.D., Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, presented a poster entitled, Quality of Life in Patients with Bardet-Biedl Syndrome in a Setmelanotide Phase 3 Trial.
  • Rhythm also presented new hunger reduction data from its exploratory Phase 2 Basket Trial evaluating setmelanotide in patients with obesity due to variants of the SRC1 gene or the SH2B1 gene.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • IMCIVREE is the first-ever FDA-approved and EC- and MHRA-authorized therapy for patients with these rare genetic diseases of obesity.